

## DAFTAR PUSTAKA

1. Biutifasari V. *Extended Spectrum Beta-Lactamase (ESBL)*. 2018;(1):1-11.
2. K B. *Past and Present Perspectives on SS-Lactamases.*; 2018.:1-20
3. Sloan C, Edwards CJ. *Extended Spectrum Beta-Lactamase. Emerg Manag Infect Dis Second Ed*. 2018;1(1):552-555.
4. M. Gashaw, M. Berhane SB et al. Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study. *Antimicrob Resist Infect Control*. 2018;7(1):138.
5. Woo DA, Schulze KA, McGuire MK. The Effect of COVID-19 On Antibiotic Resistance. *Pacific J Heal*. 2023;6(1):1-7.
6. Quan J, Dai H, Liao W, et al. Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study. *J Infect*. 2021;83(2):175-181.
7. Anggraini D, Hasanah U, Savira M, D Fauzia, Irawan D RR. Prevalensi dan Pola Sensitivitas Enterobacteriaceae Penghasil ESBL di RSUD Arifin Achmad Pekanbaru. *J Kedokt Brawijaya*. 2018;30(1):27-42.
8. Fadil M. Gambaran Sensitivitas Bakteri Penghasil Enzim Extended Spectrum Beta-Lactamase terhadap Beberapa Antimikroba di RSUP DR. M. Djamil Padang Pada Periode 2018-2019. *Jurnal Ilmu Kesehatan Indonesia*. 2022;2(2):87-94
9. Duilla H. Prevalensi Infeksi Oleh Bakteri Penghasil Extended Spectrum Beta Lactamase di RSUP DR.M Djamil Padang Tahun 2011-2013. *Fak Kedokt Univ Andalas*. 2016.:66-79
10. Yuwono. Identifikasi Gen SHV pada Enterobacteriaceae Produsen Extended-Spectrum Beta-Lactamases (ESBLs). *Syifa' MEDIKA*. 2013;4(1):10-11.
11. Shaikh S, Fatima J, Shakil S, Rizvi SMD KM. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi J Biol Sci*. 2015;22(1):90-101.
12. Kemenkes. Pedoman Umum Penggunaan Antibiotik. Peraturan Menteri Kesehatan *NO 72 TAHUN 2016*; 2017.
13. Pitout GP and JD. Extended-spectrum  $\beta$ -lactamase producing Enterobacteriaceae: update on molecular epidemiology and treatment options. *Drugs*. 2019;79(14):1529–1541.
14. Katzung B G. Basic Clinical Pharmacology. In: *14th Ed North America : McGraw Education*. ; 2018:642-643.
15. Clasen J, Birkegard AC, Græsbøll K FA. Evolution of TEM-type extended-spectrum  $\beta$ -lactamases in Escherichia coli by cephalosporins. *JGlobal Antimicroba Resist*. 2019;1(19):32-39.

16. Jawetz, Melnick A. Mikrobiologi Kedokteran. In: *27th Ed. Jakarta: EGC.* 2017:746-747.
17. Ghafourian S, Sadeghifard N, Soheili S SZ. Extended spectrum beta-lactamases: Definition, classification and epidemiology. *Curr Issues Mol Biol.* 2015;17(1):11-22.
18. Agus Sangka Pratama, Natsir Djide M NMM. Identifikasi Genotip CTX-M Pada *Escherichia coli* Penghasil *Extended Spectrum Beta Lactamase* (ESBL) yang Resisten pada Cephalosporin Generasi III Di RSUP Wahidin Sudirohusodo Makassar. *Majalah Farmasi Dan Farmakologi.* 2019;23(1):5-9
19. Paterson DL BR. Extended-Spectrum  $\beta$ -Lactamase: A Clinical Update. *Clin Microbiol Rev.* 2015;18(4):65-86.
20. Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G et al. National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by Enterobacteriaceae Producing Extended-Spectrum  $\beta$ -Lactamases. *ACC.* 2015;54(12):5099-5104.
21. WHO. Global guidelines for the prevention of surgical site infection. *J Hosp Infect.* 2017;95(2):135-136.
22. Bengoechea JA PJ. Klebsiella pneumoniae infection biology: living to counteract host defences. *FEMS Microbiol Rev.* 2019;43(2):44.
23. Heras IP, Gomez JCS, Martin PB, Pablo LR PB. Community-onset *extended-spectrum  $\beta$ -lactamase* producing *Escherichia coli* in urinary tract infections in children from 2015 to 2016: Prevalence, risk factors, and resistances. *Medicine (Baltimore).* 2017;96(50):1-3.
24. Rao S. Extended Spectrum Beta-Lactamases: A Comprehensive Review. *Microrao.* 2015:1-8.
25. Mahon CR, Walker Kimberly E, Lehman Donald MG. Enterobacteriaceae In Textbook of Diagnostic Microbiology. In: *5th Ed. WB Saunders Elsevier Inc.;* 2015:21-27.
26. Kawamura K, Nagano N, Suzuki M, Wachino J, Kimura K AY. ESBL-producing *Escherichia coli* and Its Rapid Rise among Healthy People. 2017;5(4):122-150.
27. Blanco VM, Maya JJ, Correa A, Perenguez M, Muñoz JS M, G. Prevalence and risk factors for extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli*. *Enferm Infecc Microbiol Clin.* 2016;34(4):59-65.
28. Bakri, Z., Hatta, M., & Massi MN. Deteksi Keberadaan Bakteri *Escherichia coli* O157 : H7 pada Feses Penderita Diare dengan Metode Kultur dan PCR Detection of Existence of Bacterium *Escherichia coli* O157 : H7 In Feces of Diarrhea Patients by Culture and PCR. *JST Kesehatan.* 2015;5(2):184-192.
29. Quan J, Zhao D, Liu L, Chen Y, Zhou J JY. igh prevalence of ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* in community-onset

- bloodstream infections in China. *Antimicrob Chemother* 72. 2017:273-280.
30. Martin RM BM. Colonization, Infection, and the Accessory Genome of *Klebsiella pneumoniae*. *Front Cell Infect Microbiol*. 2018;8(4):13-15.
  31. Feng DY, Zhou YQ, Zou XL, Zhou M, Zhu JX WY. Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou. *Infect Drug Resist*. 2019;12:993-1000.
  32. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13ed. In: *McGraw-Hill Education*. McGraw-Hill Education; 2017.
  33. Iyer RN. Beta lactam: *Comprehensive Pharmacology*. Elsevier. 2022:3-63.
  34. K S. Cephalosporins: Pharmacology and Chemistry. *Pharm Biol Eval*. 2017;4(6):234-238.
  35. Lin TC, Hung YP, Lin WT, Dai W, Huang YL, Ko WC. Risk factors and clinical impact of bacteremia due to carbapenem-nonsusceptible Enterobacteriaceae: A multicenter study in southern Taiwan. *J Microbiol Immunol Infect*. 2021;54(6):1122-1129.
  36. Brahim ME, Abbas M, Al-Shahrai AM EB. henotypic Characterization and Antibiotic Resistance Patterns of Extended-Spectrum  $\beta$ -Lactamase- and AmpC  $\beta$ -Lactamase-Producing Gram-Negative Bacteria in a Referral Hospital, Saudi Arabia. *PJ Infect Dis Med Microbiol*.2019:605494.
  37. Santajit S IN. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. *Biomed Res Int*. 2016;16.
  38. H. Fazeli, S. Moghim and DZ. Antimicrobial resistance pattern and spectrum of multiple-drug-resistant enterobacteriaceae in Iranian hospitalized patients with cancer. *Adv Biomed Res*. 2018;7.
  39. Jomehzadeh N. Molecular detection of ESBL- and carbapenemase-producing *Klebsiella pneumoniae* isolates in southwest Iran. 2022:1-14.
  40. Wayne P. Clinical and Laboratory Standards Institute (CLSI) 2017 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Sevent Informational Supplement. *CLSI*. 2017;37(1):100.
  41. Disease. ES of CM and I. Extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae: Detection of Resistance Mechanisms and Specific Resistances of Clinical and/or Epidemiological Importance Guidelines. *EUCAST*. 2017:16-17.
  42. DH P. Microbial identification using the bioMérieux VITEK® 2 system. *Encycl Rapid Microbiol Methods*. 2015;2:1-32.
  43. Prihatini, Aryati H. Identifikasi Cepat Mikroorganisme Menggunakan Alat VITEK-2. *Indones J Clin Pathol Med Lab*. 2018;13(3):192-32.



44. T, Naas, Cotellon G, Ergani A NP. Real-time PCR for Detection of blaOXA-48 Genes from Stools. *J Antimicrob Chemother.* 2015;68(4):101-105.
45. Husna A, Rahman MM, Badruzzaman ATM, Sikder MH, Islam MR, Rahman MT, Alam J AH. Extended-Spectrum  $\beta$ -Lactamases (ESBL): Challenges and Opportunities. *Biomedicines.* 2023;11(11):2937.
46. Kurniawathi NLR, Setyojatkiko I, Budayanti NNS. Karakteristik Antibiogram Isolat *Escherichia coli* dan *Klebsiella pneumoniae* Dari Ruang Intensive Care Unit dan Non-Intensive Care Unit Di RSUP Sanglah Selama Tahun 2018-2020. *J Kedokt.* 2021;7(1):8.
47. Indrasari DD, Koendhori EB, Kuntaman K. impact of the COVID-19 pandemic on antimicrobial resistance at Dr. Soetomo Academic Hospital of Surabaya. *Int J Health Sci (Qassim).* 2022;6(6):1058-1072.
48. Maharani YR, Yuniarti N, Puspitasari I. Prevalensi Bakteri Extended-Spectrum Beta-Lactamase dan Evaluasi Kesesuaian Antibiotik Definitif pada Pasien Rawat Inap Di RSUP Dr Soeradji Tirtonegoro Klaten. *Maj Farm.* 2021;17(2):167-165.
49. Ejaz H, Qamar MU, Farhana A, et al. The Rising Tide of Antibiotic Resistance: A Study on *Extended-Spectrum Beta-Lactamase* and Carbapenem-Resistant *Escherichia coli* and *Klebsiella pneumoniae*. *J Clin Lab Anal.* 2024;38(10):25081.
50. Castanheira M, Simner PJ, Bradford PA. Extended-spectrum  $\beta$ -lactamases: An update on their characteristics, epidemiology and detection. *JAC-Antimicrobial Resist.* 2021;3(3).
51. Riedel S, Hobden JA MS. *Jawetz, Melnick and Adelberg's Medical Microbiology: 28th Edition.*; 2019.;746-747.
52. Paczosa MK MJ. *Klebsiella pneumoniae*: Going on the Offense with a Strong Defense. *Microbiol Mol Biol Rev.* 2016;80(3):629–61.
53. Surgers L, Boyd A, Girard PM, Arlet G DD. Biofilm formation by ESBL-producing strains of *Escherichia coli* and *Klebsiella pneumoniae*. *Int J Med Microbiol.* 2019;309(1):13-18.
54. Alkeskas A, Ogrodzki P, Saad M, Masood N, Rhoma NR, Moore K, Farbos A, Paszkiewicz K FS. The molecular characterisation of *Escherichia coli* K1 isolated from neonatal nasogastric feeding tubes. *BMC Infect Dis.* 2015;15:449.
55. Bezabih YM, Sabiiti W, Alamneh E, et al. The global prevalence and trend of human intestinal carriage of ESBL-producing *Escherichia coli* in the community. *J Antimicrob Chemother.* 2021;76(1):22-29.
56. Wibisono FJ. Potensi *Escherichia Coli* Sebagai Foodborne Zoonotic Disease. *VITEK Bid Kedokt Hewan.* 2015;5:7.
57. Neog, N., Phukan, U., Puzari M et al. *Klebsiella oxytoca* and Emerging Nosocomial Infections. *Curr Microbiol.* 2021;78:1115–1123.

58. Ahmad Q, Sabrina T, Diba MF, Amalia E, Putra RA. Gambaran Infeksi *Klebsiella pneumoniae* Penghasil Extended- spectrum  $\beta$  -lactamase (ESBL) Pada Pasien COVID-19 di RSUP DR. Mohammad Hoesin. *Jambi Medical Journal*. 2022;10(2):186-198.
59. Elmawati EW, Pratiwi DIN, Muthmainah N, Biworo A. Antibiotic Susceptibility Pattern of Extended-Spectrum Beta-Lactamase-Producing *Klebsiella Pneumoniae* and *Escherichia Coli*. *Indones J Clin Pathol Med Lab*. 2021;27(3):282-288.
60. Muztika SA, Nasrul E, Alia E. Prevalensi dan Pola Sensitivitas Antibiotik *Klebsiella pneumoniae* dan *Escherichia coli* Penghasil Extended Spectrum Beta Laktamase di RSUP Dr. M Djamil Padang. *J Kesehatan Andalas*. 2020;9(2):189.
61. Budayanti NS, Suryawan K, Iswari IS, Sukrama DM. The Quality of Sputum Specimens as a Predictor of Isolated Bacteria From Patients With Lower Respiratory Tract Infections at a Tertiary Referral. 2019;6(4):1-6.
62. Peng Z, Zhou J, Tian L. Pathogenic characteristics of sputum and bronchoalveolar lavage fluid samples from patients with lower respiratory tract infection in a large teaching hospital in China: A retrospective study. *BMC Pulm Med*. 2020;20(1):1-7.
63. Yusrina BE, Jiwintarum Y, Pauzi I, Manu TT. Perbedaan Jenis Spesimen Urine Terhadap Hasil Pemeriksaan Kimiawi Urine Metode Carik Celup. *J Indones Lab Technol Student*. 2023;2(1):62-64.
64. Romyasamit C, Sornsenee P, Kawila S SP. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: insights from a tertiary hospital in Southern Thailand. *Microbiol Spectrum*. 2024;12(7):213-24
65. Syahrir S, Tirmanidhana F, Raodhah S BE. Analisis Pelaksanaan Pencegahan dan Pengendalian Infeksi Nosokomial Di ICU RSUD Labuang Baji Makassar. *HIGIENE: Jurnal Kesehatan Lingkungan*. 2018;4(2):67-73.
66. Harapan IK, Tahulending A, Tumbol MVL. Karakteristik Resistensi *Klebsiella pneumoniae* yang Resisten Karbapenem pada Beberapa Rumah Sakit di Indonesia dan Pemeriksaan Laboratorium. *Pros Semin Nas Tahun 2018 Menuju Masy Sehat, Berkarakter dan Berprestasi*. 2018;1(3):636-650.
67. Wiandanie G, Kurniati I, Sufa HI, et al. Extended Spektrum Beta Lactamase Pada Pasien. *Syntax Lit*. 2024;9(4).
68. Bader JC, Lakota EA, Dale GE, Sader HS, Rex JH, Ambrose PG BS. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia. *Antimicrob Agents Chemother*. 2019;63(3).
69. Block M BD. Aminoglycosides. *StatPearls Publ*. 2024.
70. Ku YH, Yu WL. Cefoperazone/sulbactam: New composites against

multiresistant gram negative bacteria? *Infect Genet Evol.* 2021;88(12):104707.

71. Lai, C.C., Chen, C.C., Lu, Y.C., Chuang, Y.C., Tang HJ. Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms. *Infect Drug Resist.* 2018;12:25-29.
72. Mahdizade Ari M, Dashtbin S, Ghasemi F, Shahroodian S, Kiani P, Bafandeh E, Darbandi T, Ghanavati R DA. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review. *Front Cell Infect Microbiol.* 2023;27(13).
73. Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *Eur J Clin Microbiol Infect Dis.* 2022;41(7):1003-1022.
74. Pais GM, Chang J, Barreto EF, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. *Clin Pharmacokinet.* 2022;61(7):929-953.
75. Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, et al. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel  $\beta$ -Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales. *Antimicrob Agents Chemother.* 2022;66(2):1-10.
76. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D CC. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum  $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR-P. aerug). *Clin Infect Dis.* 2021;72(7):169-183.
77. Palacios-Baena ZR, Giannella M, Manissero D, et al. *Risk Factors for Carbapenem-Resistant Gram-Negative Bacterial Infections: A Systematic Review.* Vol 27. European Society of Clinical Microbiology and Infectious Diseases; 2021;27(2):228-235.